Adam Hanna
About Adam Hanna
Adam Hanna is a Senior Finance Manager at Boston Scientific, overseeing financial planning and analysis for the Interventional Cardiology division. He has extensive experience in financial analysis, econometric modeling, and integrating business processes following corporate acquisitions.
Senior Finance Manager at Boston Scientific
Adam Hanna currently holds the position of Senior Finance Manager at Boston Scientific. He has been with the company since 2013, steadily rising through the ranks. Prior to his current role, he has served as both Finance Manager and Principal Financial Analyst. In his current capacity, he oversees financial planning and analysis for the Interventional Cardiology division, contributing to its significant growth.
Previous Roles at SUPERVALU
Before joining Boston Scientific, Adam Hanna spent several years at SUPERVALU in various roles. From 2008 to 2013, he held multiple positions including Financial Analyst, Senior Financial Analyst, Business Support Manager, and Promotions Manager. His tenure at SUPERVALU in Eden Prairie, MN provided him with a diverse set of skills in financial analysis and business support.
Educational Background in Economics
Adam Hanna graduated from Saint John's University with a Bachelor of Arts in Economics. His academic background laid the foundation for his expertise in econometric and statistical modeling, skills he applies in his financial analysis and forecasting work. He completed his studies in 2006.
Experience as a Professional Athlete
Before embarking on his corporate career, Adam Hanna was a professional athlete for two years, from 2006 to 2008. This experience provided him with unique perspectives and skills that he later transitioned to his roles in finance and business management.
Expertise in Business Process Integration
Adam Hanna has considerable expertise in integrating business processes and systems following corporate acquisitions. This skill set has been instrumental in his role at Boston Scientific, where he has contributed to the financial stability and growth of the Interventional Cardiology division.